Open Access

Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target

  • Authors:
    • Hoon Hur
    • Yi Xuan
    • Young Bae Kim
    • Gwang Lee
    • Wooyoung Shim
    • Jisoo Yun
    • In-Hye Ham
    • Sang-Uk Han
  • View Affiliations

  • Published online on: November 6, 2012     https://doi.org/10.3892/ijo.2012.1687
  • Pages: 44-54
  • Copyright: © Hur et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In contrast to mitochondria in healthy cells, which utilize oxidative phosphorylation, malignant cells undergo elevated glycolysis for energy production using glucose. The objectives of this study were to evaluate whether the expression of various molecules, including pyruvate dehydrogenase kinase-1 (PDK-1), is involved in the altered glucose metabolism associated with gastric cancer prognosis and to assess the role of a therapeutic agent in targeting glucose metabolism in gastric cancer. Immunohistochemistry was performed on gastric cancer tissues obtained from 152 patients who underwent curative resection to assess the expression of hypoxia-inducible factor-1α (HIF-1α), glucose transporter-1 (GLUT-1), hexokinase-2 (HK-2) and PDK-1. In an in vitro analysis, the lactate production and glucose uptake levels, cellular viability and 5-fluorouracil (5-FU) responses were evaluated before and after treatment with dichloroacetate (DCA), a PDK-1 inhibitor, in the MKN45 and AGS gastric cancer cell lines and in the non-cancerous HEK293 cell line. GLUT-1 and PDK-1 expression was significantly associated with tumor progression, although only PDK-1 expression was an independent prognostic factor for patients who received 5-FU adjuvant treatment. There was no significant difference in cell viability between the HEK293 and gastric cancer cell lines following DCA treatment. However, DCA treatment reduced lactate production and increased responsiveness to 5-FU in MKN45 cells, which expressed high levels of PDK-1 in comparison to the other cell lines. Thus, PDK-1 may serve as a biomarker of poor prognosis in patients with gastric cancer. In addition, PDK-1 inhibitors such as DCA may be considered an additional treatment option for patients with PDK-1-expressing gastric cancers.
View Figures
View References

Related Articles

Journal Cover

January 2013
Volume 42 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hur H, Xuan Y, Kim YB, Lee G, Shim W, Yun J, Ham I and Han S: Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol 42: 44-54, 2013
APA
Hur, H., Xuan, Y., Kim, Y.B., Lee, G., Shim, W., Yun, J. ... Han, S. (2013). Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. International Journal of Oncology, 42, 44-54. https://doi.org/10.3892/ijo.2012.1687
MLA
Hur, H., Xuan, Y., Kim, Y. B., Lee, G., Shim, W., Yun, J., Ham, I., Han, S."Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target". International Journal of Oncology 42.1 (2013): 44-54.
Chicago
Hur, H., Xuan, Y., Kim, Y. B., Lee, G., Shim, W., Yun, J., Ham, I., Han, S."Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target". International Journal of Oncology 42, no. 1 (2013): 44-54. https://doi.org/10.3892/ijo.2012.1687